Genetic polymorphisms in microRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3982-3991

  Lin, Moubin ^a   Gu, Jian ^a   Eng, Cathy ^a   Ellis, Lee M ^a   Hildebrandt, Michelle A ^a   Lin, Jie ^a   Huang, Maosheng ^a   Calin, George A ^a   Wang, Dingzhi ^a   DuBois, Raymond N ^a   Hawk, Ernest T ^a   Wu, Xifeng ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE DERIVATIVE; MICRORNA;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CARCINOMA; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICRORNA 219 GENE; MICRORNA 608 GENE; MICRORNA GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RNA GENE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENOTYPE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PYRIMIDINES; RECURRENCE; TREATMENT OUTCOME;

EID: 84863897712     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2951     Document Type: Article

References (45)

1. Gravalos C, Garcia-Escobar I, Garcia-Alfonso P, Cassinello J, Malon D, Carrato A. Adjuvant chemotherapy for stages II, III and IV of colon cancer. Clin Transl Oncol 2009;11:526-33.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet 2010;375:1030-47.
3. Marshall JL. Risk assessment in stage II colorectal cancer. Oncology (Williston Park) 2010;24 Suppl 1:9-13.
4. Raftery L, Goldberg RM. Optimal delivery of cytotoxic chemotherapy for colon cancer. Cancer J 2010;16:214-9.
5. Hoff PM, Saad ED, Costa F, Coutinho AK, Caponero R, Prolla G, et al. Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer 2012;11:93-100.
6. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228-34.
7. Sun G, Yan J, Noltner K, Feng J, Li H, Sarkis DA, et al. SNPs in human miRNA genes affect biogenesis and function. RNA 2009;15:1640-51.
8. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer Res 2005;65:3509-12. (Pubitemid 40616320)
9. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007;39:673-7. (Pubitemid 46676103)
10. Trang P, Weidhaas JB, Slack FJ. MicroRNAs as potential cancer therapeutics. Oncogene 2008;27 Suppl 2:S52-7.
11. Tomlinson I, Webb E, Carvajal-Carmona L, Broderick P, Kemp Z, Spain S, et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21. Nat Genet 2007;39:984-8. (Pubitemid 47185182)
12. Houlston RS, Webb E, Broderick P, Pittman AM, Di Bernardo MC, Lubbe S, et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer. Nat Genet 2008;40:1426-35.
13. Houlston RS, Cheadle J, Dobbins SE, Tenesa A, Jones AM, Howarth K, et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33. Nat Genet 2010;42:973-7.
14. Tomlinson IP, Carvajal-Carmona LG, Dobbins SE, Tenesa A, Jones AM, Howarth K, et al. Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet 2011;7:e1002105.
15. Horikawa Y, Wood CG, Yang H, Zhao H, Ye Y, Gu J, et al. Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin Cancer Res 2008;14:7956-62.
16. Yang H, Dinney CP, Ye Y, Zhu Y, Grossman HB, Wu X. Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res 2008;68:2530-7. (Pubitemid 351521830)
17. Ye Y, Wang KK, Gu J, Yang H, Lin J, Ajani JA, et al. Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) 2008;1:460-9.
18. Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest 2008;118:2600-8. (Pubitemid 351949787)
19. Boni V, Zarate R, Villa JC, Bandres E, Gomez MA, Maiello E, et al. Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan. Pharmacogenomics J 2011;11:429-36.
20. Lee HC, Kim JG, Chae YS, Sohn SK, Kang BW, Moon JH, et al. Prognostic impact of microRNA-related gene polymorphisms on survival of patients with colorectal cancer. J Cancer Res Clin Oncol 2010;136:1073-8.
21. International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-96.
22. Sherry ST, Ward M, Sirotkin K. dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 1999;9:677-9. (Pubitemid 29412785)
23. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34(Database issue):D140-4.
24. Benjamini Y, Drai D, Elmer G, Kafkafi N, Golani I. Controlling the false discovery rate in behavior genetics research. Behav Brain Res 2001;125:279-84. (Pubitemid 33000466)
25. Smits KM, Cleven AH, Weijenberg MP, Hughes LA, Herman JG, de Bruine AP, et al. Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. Pharmacogenomics 2008;9:1903-16.
26. Mano MS, Duhoux F. Colon cancer: update on adjuvant therapy. Clin Colorectal Cancer 2008;7:178-83. (Pubitemid 351758147)
27. Lin J, Horikawa Y, Tamboli P, Clague J, Wood CG, Wu X. Genetic variations in microRNA-related genes are associated with survival and recurrence in patients with renal cell carcinoma. Carcinogenesis 2010;31:1805-12.
28. Landi D, Gemignani F, Barale R, Landi S. A catalog of polymorphisms falling in microRNA-binding regions of cancer genes. DNA Cell Biol 2008;27:35-43.
29. Godai TI, Suda T, Sugano N, Tsuchida K, Shiozawa M, Sekiguchi H, et al. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy. BMC Cancer 2009;9:420.
30. Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 1999;18:477-85. (Pubitemid 29060623)
31. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907. (Pubitemid 351449681)
32. Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, et al. microRNA modulation of circadian-clock period and entrainment. Neuron 2007;54:813-29. (Pubitemid 46843524)
33. Wood PA, Du-Quiton J, You S, Hrushesky WJ. Circadian clock coordinates cancer cell cycle progression, thymidylate synthase, and 5-fluorouracil therapeutic index. Mol Cancer Ther 2006;5:2023-33. (Pubitemid 44336574)
34. Clague J, Lippman SM, Yang H, Hildebrandt MA, Ye Y, Lee JJ, et al. Genetic variation in MicroRNA genes and risk of oral premalignant lesions. Mol Carcinog 2010;49:183-9.
35. Mishra PJ, Bertino JR. MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine. Pharmacogenomics 2009;10:399-416.
36. Faggad A,Budczies J, Tchernitsa O, Darb-Esfahani S, Sehouli J, Muller BM, et al. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression. J Pathol 2010;220:382-91.
37. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer 2010;10:389-402.
38. Svoboda M, Izakovicova Holla L, Sefr R, Vrtkova I, Kocakova I, Tichy B, et al. Micro-RNAs miR125b and miR137 are frequently upregulated in response to capecitabine chemoradiotherapy of rectal cancer. Int J Oncol 2008;33:541-7.
39. Melo SA, Moutinho C, Ropero S, Calin GA, Rossi S, Spizzo R, et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010;18:303-15.
40. Honma K, Takemasa I, Matoba R, Yamamoto Y, Takeshita F, Mori M, et al. Screening of potential molecular targets for colorectal cancer therapy. Int J Gen Med 2009;2:243-57.
41. Woo IS, Jang HS, Eun SY, Kim HJ, Ham SA, Lee JH, et al. Ran suppresses paclitaxel-induced apoptosis in human glioblastomacells. Apoptosis 2008;13:1223-31.
42. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:635-47. (Pubitemid 40343076)
43. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998;90:675-84. (Pubitemid 28222141)
44. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001;85:692-6. (Pubitemid 32929467)
45. Nakajima G, Hayashi K, Xi Y, Kudo K, Uchida K, Takasaki K, et al. Noncoding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer. Cancer Genomics Proteomics 2006;3:317-24. (Pubitemid 44701551)